LEGN — Legend Biotech Corporation

Legend Biotech (LEGN) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Trade Sales: CARVYKTI generated approximately $524 million in net trade sales, an 84% increase year-over-year and a 19% increase from Q2 2025.
• Total Revenues: Reported total revenues were $272 million, driven by collaboration revenue growth of 84% year-over-year.
• Net Loss: The company reported a net loss of $40 million, with an adjusted net loss of $19 million, improving from a $70 million operating loss in Q3 2024 to $43 million in Q3 2025.
• Gross Margin: Consistent at 57%.
• Cash Position: Approximately $1 billion in cash and equivalents, supporting ongoing operational and capital expenditures.

2. Strategic Updates and Business Highlights:

• CARVYKTI Launch Success: Over 9,000 patients treated, with a strong focus on earlier line settings, which account for 60% of U.S. utilization.
• Regulatory Milestones: FDA approval for CARVYKTI's overall survival benefit label update, enhancing its competitive position.
• Clinical Data: Positive long-term survival data presented at ASCO, with one-third of heavily pretreated patients remaining alive and progression-free for over five years.
• Manufacturing Capacity: Expansion plans are on track, with expectations to treat over 10,000 patients annually by 2026.
• Community Engagement: Increased efforts to expand CARVYKTI's presence in community settings, with 132 authorized treatment centers in the U.S. and ongoing discussions to enhance outreach.

3. Forward Guidance and Outlook:

• Profitability Expectations: Anticipating CARVYKTI profitability by the end of 2025 and company-wide profitability in 2026, excluding foreign exchange impacts.
• Growth Strategy: Continued focus on expanding market penetration, particularly in community settings and international markets, with a goal to reach 20,000 doses annually in the future.

4. Bad News, Challenges, or Points of Concern:

• Operational Challenges: Despite strong sales, the company faces the challenge of transitioning from a supply-constrained to a demand-constrained environment, necessitating effective demand mobilization strategies.
• Competitive Pressures: Potential competition from new CAR-T therapies, with uncertainty regarding the efficacy of competitor products not yet fully disclosed.
• Regulatory and Clinical Risks: Ongoing discussions with the FDA regarding MRD as a registrational endpoint and the impact of recent studies on treatment protocols for neurotoxicity.

5. Notable Q&A Insights:

• Community Strategy: Executives emphasized the importance of engaging community physicians and expanding treatment capabilities in outpatient settings, with 50% of patients currently treated on an outpatient basis.
• Capacity Utilization: The company is nearing full utilization of its manufacturing capacity, with expectations to achieve this by 2026.
• ASH Meeting Expectations: Anticipation of presenting compelling data at the upcoming ASH meeting, which could further solidify CARVYKTI's market position.
• Proactive Measures: Discussion on adjusting strategies for mitigating neurotoxicity based on recent findings, focusing on effective bridging therapies to reduce tumor burden prior to CAR-T treatment.

Overall, Legend Biotech reported a strong quarter with significant growth in CARVYKTI sales and a clear path toward profitability, while also navigating competitive pressures and operational challenges.